Hunter R. Murdock Sells 7,500 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) General Counsel Hunter R. Murdock sold 7,500 shares of the stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $100.26, for a total transaction of $751,950.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Axsome Therapeutics Price Performance

NASDAQ AXSM opened at $100.69 on Friday. Axsome Therapeutics, Inc. has a 52 week low of $72.21 and a 52 week high of $139.13. The company has a current ratio of 2.03, a quick ratio of 1.96 and a debt-to-equity ratio of 3.48. The stock has a market cap of $4.96 billion, a price-to-earnings ratio of -17.45 and a beta of 0.47. The company has a 50-day moving average price of $106.75 and a two-hundred day moving average price of $107.04.

Analyst Upgrades and Downgrades

A number of research firms have commented on AXSM. Cantor Fitzgerald upgraded shares of Axsome Therapeutics to a “strong-buy” rating in a research note on Wednesday, May 14th. Wells Fargo & Company reiterated an “overweight” rating and set a $165.00 price objective (up from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 6th. Royal Bank Of Canada reduced their price objective on shares of Axsome Therapeutics from $193.00 to $186.00 and set an “outperform” rating on the stock in a research note on Thursday, June 12th. Oppenheimer began coverage on shares of Axsome Therapeutics in a research note on Tuesday, June 3rd. They set an “outperform” rating and a $185.00 price objective on the stock. Finally, Robert W. Baird increased their price objective on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the company an “outperform” rating in a research note on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Axsome Therapeutics has a consensus rating of “Buy” and an average target price of $172.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC grew its position in Axsome Therapeutics by 46.5% in the 4th quarter. Intech Investment Management LLC now owns 16,028 shares of the company’s stock worth $1,356,000 after purchasing an additional 5,087 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $14,771,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Axsome Therapeutics by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company’s stock worth $27,755,000 after acquiring an additional 5,438 shares during the period. Aigen Investment Management LP acquired a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $395,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Axsome Therapeutics by 20.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company’s stock worth $4,877,000 after acquiring an additional 9,928 shares during the period. Institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.